PRESS RELEASE

FOR IMMEDIATE RELEASE

European CE Approval for gumEase® Cryoanesthetic Device

Laguna Hills, California USA (April 20, 2007) BioMeDevice Ltd. has announced Conformité Européne (CE) mark approval for the new gumEase® G100 cryoanesthetic device.

As a result, gumEase® G100 device is approved for sales and distribution with in the 28 European Union (EU) and 3 European Free Trade Association (EFTA) member states. "This is a great accomplishment for the BioMeDevice team", says BioMeDevice CEO Brice Yoder, "and validates the great benefits that several years of trials and design will have on dental care and pain management for the European Union".

gumEase® provides dental pain relief without the need for drugs. Not only is gumEase® effective through a wide variety of dental procedures, it is easy to apply and use for outpatients as well. The patented gumEase® technology designed and developed by BioMeDevice Ltd. is a revolutionary step forward in the concept of dental anesthesia. It allows dentists, orthodontists and certain oral medical and surgical specialties to almost completely eliminate the use of needles and drugs to provide anesthesia or numbness during most procedures.

BioMeDevice Ltd. has entered into a manufacturing and distribution partnership with Cryodevices Ireland, Ltd. and Medisize Ireland Ltd. to manufacture gumEase® with the same rigorous standards of the US FDA.